Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy
Perno, C.F.; Cozzi-Lepri, A.; Balotta, C.; Forbici, F.; Violin, M.; Bertoli, A.; Facchi, G.; Pezzotti, P.; Angarano, G.; Arici, C.; Narciso, P.; Orani, A.; Raise, E.; Scalzini, A.; Poggio, A.; Ippolito, G.; Moroni, M.; Monforte, A.D.
Antiviral Therapy 6(3): 195-198
2001
ISSN/ISBN: 1359-6535 PMID: 11808755 Document Number: 526845
Document emailed within 1 workday
Related Documents
Mouroux, M.; Descamps, D.; Izopet, J.; Yvon, A.; Delaugerre, C.; Matheron, S.; Coutellier, A.; Valantin, M.A.; Bonmarchand, M.; Agut, H.; Massip, P.; Costagliola, D.; Katlama, C.; Brun-Vezinet, F.; Calvez, V. 2001: Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy Antiviral Therapy 6(3): 179-183Abed, Y.; Baz, M.; Boivin, G. 2006: Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds Antiviral Therapy 11(8): 971-976
Katlama, C.; Ingrand, D.; Loveday, C.; Clumeck, N.; Mallolas, J.; Staszewski, S.; Johnson, M.; Hill, A.M.; Pearce, G.; McDade, H. 1996: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. a randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group JAMA 276(2): 118-125
Lapiński, T.W.; Parfieniuk-Kowerda, A.; Trzos, A.; Jaroszewicz, J.; Kowalczuk, O.; Nikliński, J.; Flisiak, R. 2013: HBV mutations associated with lamivudine therapy Przeglad Epidemiologiczny 67(4): 611
Rajesh, L.; Karunaianantham, R.; Narayanan, P.R.; Swaminathan, S. 2009: Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients Aids Research and Human Retroviruses 25(11): 1179-1185
Mauss, S.; Milinkovic, A.; Hoffmann, C.; Holm, S.; Berger, F.; Martínez, E.; Kuhlmann, B.; Gatell, J.é; Schmutz, G. 2005: Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine Aids 19(1): 101-102
Lawn, S.D.; Wood, R. 2006: Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: implications for resource-limited settings? Journal of Infectious Diseases 194(10): 1467-8; Author Reply 1468
Staszewski, S.; Keiser, P.; Montaner, J.; Raffi, F.; Gathe, J.; Brotas, V.; Hicks, C.; Hammer, S.M.; Cooper, D.; Johnson, M.; Tortell, S.; Cutrell, A.; Thorborn, D.; Isaacs, R.; Hetherington, S.; Steel, H.; Spreen, W. 2001: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial JAMA 285(9): 1155-1163
Gartland, M. 2001: AVANTi 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients Antiviral Therapy 6(2): 127-134
Poerksen, G.; Pollock, L.; Moons, P.; Chesshyre, E.; Burger, D.; Khoo, S.; Molyneux, E. 2010: Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets Antiviral Therapy 15(3): 343-350
Goodgame, J.C.; Pottage, J.C.; Jablonowski, H.; Hardy, W.D.; Stein, A.; Fischl, M.; Morrow, P.; Feinberg, J.; Brothers, C.H.; Vafidis, I.; Nacci, P.; Yeo, J.; Pedneault, L. 2000: Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team Antiviral Therapy 5(3): 215-225
Tseng, T-Chung.; Liu, C-Jen.; Wang, C-Chi.; Chen, P-Jer.; Lai, M-Yang.; Chen, D-Shinn.; Kao, J-Horng. 2009: Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels Antiviral Therapy 14(2): 203-210
Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Thielman, N.M.; Ostermann, J.; Whetten, K.; Whetten, R.; Itemba, D.; Maro, V.; Pence, B.; Reddy, E. 2014: Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer Journal of Acquired Immune Deficiency Syndromes 65(3): E104-E109
Zhou, D.-Y.; Lin, L.-Y.; Wang, H.; Huang, J.-S. 2003: The relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter mutations Hepatobiliary and Pancreatic Diseases International: Hbpd Int 2(1): 85-89
Puthanakit, T.; Jourdain, G.; Hongsiriwon, S.; Suntarattiwong, P.; Chokephaibulkit, K.; Sirisanthana, V.; Kosalaraksa, P.; Petdachai, W.; Hansudewechakul, R.; Siangphoe, U.; Suwanlerk, T.; Ananworanich, J.; Bunupuradah, T.; Phasomsap, C.; Kaew-on, P.; Kanjanavanit, S.; Hinjiranandana, T.; Layangool, P.; Kamonpakorn, N.; Buranabanjasatean, S.; Ngampiyaskul, C.; Chotpitayasunondh, T.; Chanpradub, S.; Leawsrisuk, P.; Chearskul, S.; Vanprapar, N.; Phongsamart, W.; Lapphra, K.; Chearskul, P.; Wittawatmongkol, O.; Prasitsuebsai, W.; Intalapaporn, K.; Kongstan, N.; Pannin, N.; Maleesatharn, A.; Khumcha, B.; Aurpibul, L.; Wongnum, N.; Nadsasarn, R.; Lumbiganon, P.; Tharnprisan, P.; Udompanich, T.; Yentang, M.; Khonponoi, A.; Maneerat, N.; Denjunta, 2010: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy HIV Medicine 11(9): 565-572
Costa, C.R.; de Lemos, J.A.; Passos, X.S.; de Araújo, C.R.; Cohen, A.J.; Souza, L.úc.K.H.E.; Silva, M.d.R.ár.R. 2006: Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era Mycopathologia 162(1): 45-50
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Rossi, S.M.G.d.; Maluf, E.C.P.; Carvalho, D.S.; Ribeiro, C.E.L.; Battaglin, C.R.P. 2012: Impact of antiretroviral therapy under different treatment regimens Revista Panamericana de Salud Publica 32(2): 117-123
Gatanaga, H. 2002: Clinical impact of combination antiretroviral therapy Nihon Rinsho. Japanese Journal of Clinical Medicine 60(4): 739-744